All In Biotech

Drug Trial Radar · NCT02432833

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients

Last checked: Nov 20, 2026Latest source record: Apr 13, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

428

Actual

Start

May 2015

Primary completion

Jan 24, 2017

Study completion Jan 24, 2017

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
May 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare tacrolimus dosing of the new Envarsus®-based immunosuppressive regimen with current clinical practice (Prograf or Advagraf) over 6 months following de novo renal transplantation in a real-life setting in different European Countries.

Conditions

  • End Stage Renal Disease

Interventions

  • ENVARSUS®Drug

    Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus

  • PROGRAF®Drug

    Prograf® hard capsules, twice daily, oral formulation

  • ADVAGRAF®Drug

    Advagraf® prolonged-release hard capsules, once daily, oral formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tacrolimus total daily dose (TDD) from week 3 to month 6Time frame: from week 3 to month 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chiesi farmaceutici Spa

    Parma, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.